Health Condition 1: null- Primary Membranous Nephropathy
Conditions
Interventions
Intervention1: Anti-PLA2R Targeted therapy: Patients will be treated with cyclical cyclophosphamide and steroid therapy
(Intravenous methylprednisolone 1 g/d for 3 consecutive days followed by oral
Sponsors
Postgraduate Institute of Medical Education and Research
Eligibility
Inclusion criteria
Inclusion criteria: Biopsy-proven PMN, have a urinary protein excretion of >3.5 g/d or a urinary protein-to-creatinine ratio >3500 mg/g, and have a serum albumin of <=3.0 g/L, despite maximal tolerated dose of NIAT (angiotensinâ??converting enzyme inhibitors and/or angiotensin 2 receptor blockers, diuretics, and statin) for 6 months or those with complications of nephrotic syndrome viz; vascular thrombosis, respiratory tract infections requiring hospitalization or severe anasarca despite maximal tolerable dose of diuretics
Exclusion criteria
Exclusion criteria: Patients with secondary MN, estimated glomerular filtration rate < 45 ml/min 1.73 m2, pregnancy, breastfeeding, immunosuppressive treatment in the 3 preceding months, hepatitis B surface antigen /anti-HCV positive and other active infectious disease will be excluded.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Remission of Nephrotic Syndrome (both Complete and Partial)Timepoint: 6, 12 and 18 months | — |
Secondary
| Measure | Time frame |
|---|---|
| Adverse events, anti-PLA2R levels and decline in estimated GFR.Timepoint: 6, 12 and 18 months | — |
Countries
India
Contacts
Public ContactRaja Ramachandran
PGIMER
Outcome results
None listed